Ventricular Tachycardia

CHICAGO — Catheter ablation improved outcomes compared with antiarrhythmic drug therapy in patients with ventricular tachycardia and ischemic cardiomyopathy, researchers reported at the American Heart Association Scientific Sessions.

A single burst of antitachycardia pacing before an implantable cardioverter defibrillator shock lowered risk for all-cause shock compared with a standard shock protocol, according to the results of the APPRAISE ATP trial.

Preeclampsia appeared to increase primiparous women’s risk for developing arrhythmia, according to results of a real-world study published in European Journal of Preventative Cardiology.

In patients with long QT syndrome, vigorous exercise did not appear to increase CV event risk vs. nonvigorous exercise regardless of age, sex or genotype, according to new data from the LIVE-LQTS study presented at Heart Rhythm 2024.

PHILADELPHIA — In people with congenital long QT syndrome, vigorous exercise did not raise risk for death or ventricular arrhythmias compared with nonvigorous exercise, according to the results of the LIVE-LQTS study.

In high-risk patients undergoing ablation for ventricular tachycardia, use of a mechanical circulatory support device did not improve clinical outcomes, researchers reported at Heart Rhythm 2023.

In adults with scar-related ventricular tachycardia, a strategy of ventricular tachycardia ablation plus implantation of a subcutaneous implantable cardioverter defibrillator led to better outcomes than use of a transvenous ICD, data show.

Abbott today announced the FDA approval and receipt of CE Mark for two of its sensor-enabled ablation catheters.